🟢 90/100

This product looks safe

  • Niacin: 50mg is 1.4× the Tolerable Upper Intake Level (35mg)
  • 25% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 50mg is 1.4× the Tolerable Upper Intake Level (35mg)

Label Data

5 Tablet(s) Serving Size
30 Servings
Other Combinations Product Type
25% Evidence Coverage

Supplement Facts — Evidence Check

50 mg (250% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 1.4× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 50mg UL 35mg
Sodium
41 mg (2% DV)
Blue C Complex (Combination)
3750 mg
Blue Sky Complex (Combination)
2200 mg

Other Ingredients

Maltodextrin Magnesium Stearate Artificial Colors

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Directions: Take 5 tablets, once per day, 60 minutes before your workout and anytime on non-workout days. After every 2 bottles (2 months), cycle off for 2 weeks before reintroducing this supplement back into your daily routine. For best results, Blue Gene(TM) should be used in combination with other Controlled Labs products, at least 1-2 gallons of water per day, and a high protein/moderate carbohydrate diet.

Initial (First Serving Only) Instructions: To assess your individual tolerance to the formula, take 1 tablet 60 minutes before working out.

⚠️ Warnings & Precautions

Keep out of the reach of children.

Do not purchase if safety seal is broken.

Warnings: You should not take this product if you have any prior medical conditions, including diabetes or high blood pressure. Consult your doctor before using this product.

Additional Information

For more details on optimizing your results, please visit: www.ControlledLabs.com

Natural Anabolic Matrix

Product Details

DSLD Entry Date 2011-11-25
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 2629
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →